Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology

Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.